Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15771005 | 0.85 | GAA (0.41) | GAAALDH1A1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL15771004 | 0.85 | GAA (0.41) | GAAALDH1A1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL10264683 | 0.84 | GAA (0.42) | GAAALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL13520135 | 0.82 | GAA (0.42) | GAAALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL499581 | 0.80 | ALDH1A1 (0.38) | GAAALDH1A1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL13521875 | 0.78 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL499642 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL499395 | 0.74 | MAPT (0.44) | GAAALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL10265159 | 0.73 | ALDH1A1 (0.36) | GAAALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL499015 | 0.72 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009975-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | GAA 1038/4885ALDH1A1 861/4885MAPT 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.